Role of combined determination of serum sB7-H3，gp73 and TAT-2 in the differential diagnosis of colorectal cancer and tubular adenoma

doi:10.3969/j.issn.1673-8640.2026.04.004

Abstract

Abstract:

Objective To investigate the role of combined determination of serum soluble B7-homologue 3（sB7-H3），Golgi protein 73（gp73） and tumor-associated trypsinogen-2（TAT-2） in the differential diagnosis of colorectal cancer and tubular adenoma. Methods A total of 86 patients with colorectal cancer（colorectal cancer group），86 patients with tubular adenoma（tubular adenoma group） and 86 healthy subjects（healthy control group） were enrolled from the First Hospital of Handan City from December 2020 to December 2022. The colorectal cancer patients were classified into stage Ⅰ-Ⅱ group（54 cases） and stage Ⅲ-Ⅳ group（32 cases） according to TNM staging. Serum levels of sB7-H3，gp73，TAT-2，carcinoembryonic antigen（CEA） and carbohydrate antigen 19-9（CA19-9） and fecal occult blood status were determined. The efficacy of single and combined determinations of each indicator in differentiating colorectal cancer and tubular adenoma was evaluated using receiver operating characteristic（ROC） curve. Multivariate Logistic regression analysis was used to assess the influencing factors of colorectal cancer occurrence. Results The serum levels of sB7-H3，gp73，TAT-2，CEA and CA19-9 and the proportion of positive fecal occult blood in healthy control group，tubular adenoma group and colorectal cancer group were increased successively（P<0.001）. The serum levels of sB7-H3，gp73，TAT-2，CEA and CA19-9 in stage Ⅲ-Ⅳ group were higher than those in stage Ⅰ-Ⅱ group（P<0.05）. Positive fecal occult blood and elevated CEA，CA19-9，sB7-H3，gp73 and TAT-2 were risk factors for colorectal cancer occurrence（P<0.05）. The areas under curves（AUC） for differentiating healthy control from tubular adenoma and differentiating healthy control from colorectal cancer by single determinations of serum CEA，CA19-9，sB7-H3，gp73 and TAT-2 and their combined determination were 0.701，0.710，0.751，0.754，0.829，0.904，and 0.781，0.758，0.809，0.780，0.798 and 0.900，respectively. The AUC for differentiating colorectal cancer and tubular adenoma were 0.701，0.718，0.730，0.739，0.710 and 0.908，respectively. Conclusions The combined determination of serum sB7-H3，gp73 and TAT-2 can be used as indicators for the differential diagnosis of colorectal cancer and tubular adenoma.

Key words: Soluble B7-homologue 3, Golgi protein 73, Tumor-associated trypsinogen-2, Colorectal cancer, Tubular adenoma, Differential diagnosis

CLC Number:

R446.1

YAN Jing, DONG Kui, WU Jie, LIU Haitao. Role of combined determination of serum sB7-H3，gp73 and TAT-2 in the differential diagnosis of colorectal cancer and tubular adenoma[J]. Laboratory Medicine, 2026, 41(4): 331-336.

Figures/Tables 9

References 22

[1]	闻杨, 董洪敏, 张红丽, 等. 重组人血管内皮抑素联合化疗治疗晚期大肠癌20例分析[J]. 贵州医药, 2016, 40(1):74-76.
[2]	刘甜甜, 郜茜. 脂联素在结直肠息肉及结直肠癌中的作用研究[J]. 临床医学进展, 2023, 13(8):12673-12678.
[3]	张晶晶, 彭琼. 大肠癌和大肠腺瘤性息肉患者外周血中G-17表达及临床意义[J]. 胃肠病学和肝病学杂志, 2020, 29(1):50-52.
[4]	SHENG Y, YAN L, LIU Q, et al. The pronounced cytotoxic effects of chimeric antigen receptor T cells targeting B7-H3 in organoids and liver xenografts derived from colorectal cancer patients[J]. Br J Cancer, 2025, 133(7):1056-1065.
[5]	赵娣, 马茂, 高向阳, 等. 高尔基体蛋白73(GP73)的研究进展[J]. 现代医学与健康研究(电子版), 2022, 6(6):25-30.
[6]	伊玉娇, 程中乐, 吴正升. 结直肠癌中高尔基体蛋白73的表达及意义[J]. 临床与实验病理学杂志, 2023, 39(6):744-747.
[7]	BJÖRKMAN K, KAPRIO T, BEILMANN-LEHTONEN I, et al. TATI,TAT-2,and CRP as prognostic factors in colorectal cancer[J]. Oncology, 2022, 100(1):22-30.
[8]	中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020年版)[J]. 中华外科杂志, 2020, 58(8):561-585.
[9]	王成龙, 赵子夜, 闫飞虎, 等. 结肠镜检查质控指标与肠镜检查后结直肠癌发生率相关性的研究现状[J]. 结直肠肛门外科, 2023, 29(3):304-308.
[10]	AZUMA T, SATO Y, OHNO T, et al. Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer[J]. PLoS One, 2020, 15(12):e0243379.
[11]	WANG L, KANG F B, ZHANG G C, et al. Clinical significance of serum soluble B7-H3 in patients with osteosarcoma[J]. Cancer Cell Int, 2018, 18:115.
[12]	马晓路, 郭林, 卢仁泉. 原发性肝细胞肝癌患者外周血指标的临床价值及其应用前景[J]. 检验医学, 2025, 40(4):309-316.
[13]	LIANG R, LIU Z, PIAO X, et al. Research progress on GP73 in malignant tumors[J]. Onco Targets Ther, 2018, 11:7417-7421.
[14]	王芳芳, 张国范, 王琪, 等. HBV感染原发性肝癌患者GP73和AFU与25(OH)D3及其与TACE术后复发转移的关系[J]. 中华医院感染学杂志, 2023, 33(11):1660-1664.
[15]	韩秋月, 章霞, 陈保富, 等. 高尔基体糖蛋白-73在非小细胞肺癌中的表达及意义[J]. 医学研究杂志, 2016, 45(1):44-47.
[16]	LIU Y, HU X, LIU S, et al. Golgi phosphoprotein 73:the driver of epithelial-mesenchymal transition in cancer[J]. Front Oncol, 2021, 11:783860.
[17]	江俊园, 唐东军, 王猛, 等. 血清GP73表达与老年前列腺癌病理分级及恶性分子表达的相关性分析[J]. 中国性科学, 2021, 30(9):40-45.
[18]	宋华勇, 张帆, 李肖芸, 等. 血清外泌体AFP、GP73及miRNA21联合检测在原发性肝癌诊断中的应用价值[J]. 中国实用医刊, 2023, 50(24):86-88.
[19]	KASURINEN A, LAITINEN A, KOKKOLA A, et al. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer[J]. Acta Oncol, 2020, 59(6):681-688.
[20]	CHEN X, HONG J, ZHAO H, et al. Establishment and clinical application of a highly sensitive time-resolved fluorescence immunoassay for tumor-associated trypsinogen-2[J]. J Fluoresc, 2022, 32(4):1501-1507.
[21]	李秋婷, 康举龄, 吴先林. 基质金属蛋白酶-2与胰腺癌关系的研究进展[J]. 广东医学, 2016, 37(7):1082-1084.
[22]	胡毅, 刘兵, 杨旭. 血清CEA、CA242、CA19-9及其联检对大肠癌的诊断价值[J]. 中国普外基础与临床杂志, 2007, 14(6):700.

组别	例数	sB7-H3/（ng·mL^-1）	gp73/（ng·mL^-1）	TAT-2/（U·mL^-1）	CEA/（ng·mL^-1）	CA19-9/（U·mL^-1）	粪便隐血阳性/ [例（%）]
结直肠癌组	86	18.62±2.05^*#	9.57±1.06^*#	28.64±3.25^*#	14.32±4.45^*#	33.56±10.71^*#	62（72.09）^*#
管状腺瘤组	86	16.77±2.04^*	8.70±1.05^*	26.14±3.17^*	9.85±2.92^*	22.15±6.63^*	28（32.56）^*
正常对照组	86	13.05±2.03	6.52±1.05	22.48±2.98	5.15±1.56	14.04±3.52	0（0）
统计值		166.303	191.344	83.970	176.347	388.707	98.695
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	sB7-H3/（ng·mL^-1）	gp73/（ng·mL^-1）	TAT-2/（U·mL^-1）	CEA/（ng·mL^-1）	CA19-9/（U·mL^-1）	粪便隐血阳性/ [例（%）]
结直肠癌组	86	18.62±2.05^*#	9.57±1.06^*#	28.64±3.25^*#	14.32±4.45^*#	33.56±10.71^*#	62（72.09）^*#
管状腺瘤组	86	16.77±2.04^*	8.70±1.05^*	26.14±3.17^*	9.85±2.92^*	22.15±6.63^*	28（32.56）^*
正常对照组	86	13.05±2.03	6.52±1.05	22.48±2.98	5.15±1.56	14.04±3.52	0（0）
统计值		166.303	191.344	83.970	176.347	388.707	98.695
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	sB7-H3/（ng·mL^-1）	gp73/（ng·mL^-1）	TAT-2/（U·mL^-1）	CEA/（ng·mL^-1）	CA19-9/（U·mL^-1）
Ⅰ~Ⅱ期组	54	18.04±2.17	8.99±1.13	27.22±3.06	12.56±3.42	29.48±8.65
Ⅲ~Ⅳ期组	32	19.60±2.04	10.55±1.52	31.04±3.32	17.28±4.89	40.44±11.37
t值		3.294	5.430	5.421	5.256	5.043
P值		<0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	sB7-H3/（ng·mL^-1）	gp73/（ng·mL^-1）	TAT-2/（U·mL^-1）	CEA/（ng·mL^-1）	CA19-9/（U·mL^-1）
Ⅰ~Ⅱ期组	54	18.04±2.17	8.99±1.13	27.22±3.06	12.56±3.42	29.48±8.65
Ⅲ~Ⅳ期组	32	19.60±2.04	10.55±1.52	31.04±3.32	17.28±4.89	40.44±11.37
t值		3.294	5.430	5.421	5.256	5.043
P值		<0.001	<0.001	<0.001	<0.001	<0.001

项目	β值	标准误	Wald值	P值	OR^①值（95%CI^②）
粪便隐血	0.296	0.137	4.657	0.031	1.344（1.028~1.758）
CEA	0.612	0.255	5.769	0.016	1.845（1.119~3.041）
CA19-9	0.673	0.218	9.543	0.002	1.961（1.279~3.006）
sB7-H3	0.987	0.135	53.486	<0.001	2.684（2.060~3.497）
gp73	1.277	0.248	26.527	<0.001	3.587（2.206~5.832）
TAT-2	0.812	0.187	18.867	<0.001	2.253（1.562~3.250）